Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:FGFR2-AHCYL1 (FusionGDB2 ID:HG2263TG10768)

Fusion Gene Summary for FGFR2-AHCYL1

Fusion gene summary

Fusion gene information	Fusion gene name: FGFR2-AHCYL1
	Fusion gene ID: hg2263tg10768
		Hgene	Tgene
	Gene symbol	FGFR2	AHCYL1
	Gene ID	2263	10768
	Gene name	fibroblast growth factor receptor 2	adenosylhomocysteinase like 1
	Synonyms	BBDS\|BEK\|BFR-1\|CD332\|CEK3\|CFD1\|ECT1\|JWS\|K-SAM\|KGFR\|TK14\|TK25	DCAL\|IRBIT\|PPP1R78\|PRO0233\|XPVKONA
	Cytomap	('FGFR2')('AHCYL1') 10q26.13	1p13.3
	Type of gene	protein-coding	protein-coding
	Description	fibroblast growth factor receptor 2BEK fibroblast growth factor receptorbacteria-expressed kinasekeratinocyte growth factor receptorprotein tyrosine kinase, receptor like 14	S-adenosylhomocysteine hydrolase-like protein 1DC-expressed AHCY-like moleculeIP(3)Rs binding protein released with IP(3)S-adenosyl homocysteine hydrolase homologS-adenosyl-L-homocysteine hydrolase 2adenosylhomocysteinase 2adoHcyase 2dendritic cell
	Modification date	20200322	20200313
	UniProtAcc	P21802	.
	Ensembl transtripts involved in fusion gene	ENST00000346997, ENST00000351936, ENST00000356226, ENST00000357555, ENST00000358487, ENST00000360144, ENST00000369056, ENST00000369059, ENST00000369060, ENST00000369061, ENST00000457416, ENST00000478859, ENST00000359354, ENST00000490349,
Fusion gene scores	* DoF score	24 X 20 X 12=5760	11 X 13 X 4=572
	# samples	38	12
	** MAII score	log2(38/5760*10)=-3.92199748799873 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(12/572*10)=-2.25298074116987 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: FGFR2 [Title/Abstract] AND AHCYL1 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	FGFR2(123243212)-AHCYL1(110551654), # samples:2
Anticipated loss of major functional domain due to fusion event.	FGFR2-AHCYL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. FGFR2-AHCYL1 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	FGFR2	GO:0008284	positive regulation of cell proliferation	8663044
Hgene	FGFR2	GO:0008543	fibroblast growth factor receptor signaling pathway	8663044\|15629145
Hgene	FGFR2	GO:0018108	peptidyl-tyrosine phosphorylation	15629145\|16844695
Hgene	FGFR2	GO:0046777	protein autophosphorylation	15629145
Tgene	AHCYL1	GO:0006378	mRNA polyadenylation	19224921
Tgene	AHCYL1	GO:0031440	regulation of mRNA 3'-end processing	19224921
Tgene	AHCYL1	GO:0038166	angiotensin-activated signaling pathway	20584908
Tgene	AHCYL1	GO:0051592	response to calcium ion	18829453

Fusion gene breakpoints across FGFR2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across AHCYL1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source

Disease

Sample

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Top

Fusion Gene ORF analysis for FGFR2-AHCYL1

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000369061	ENST00000369799	FGFR2	chr10	123243212	-	AHCYL1	chr1	110551654	+	0.000258539	0.9997415
ENST00000346997	ENST00000369799	FGFR2	chr10	123243212	-	AHCYL1	chr1	110551654	+	0.000199904	0.99980015
ENST00000369056	ENST00000369799	FGFR2	chr10	123243212	-	AHCYL1	chr1	110551654	+	0.000352547	0.9996475

Top

Fusion Genomic Features for FGFR2-AHCYL1

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	1-p	p (fusion gene breakpoint)
FGFR2	chr10	123243211	-	AHCYL1	chr1	110551655	+	2.50E-06	0.9999975
FGFR2	chr10	123243211	-	AHCYL1	chr1	110551655	+	2.50E-06	0.9999975

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for FGFR2-AHCYL1

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:123243212/chr1:110551654)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
FGFR2 P21802	.
FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269\|PubMed:12529371, ECO:0000269\|PubMed:15190072, ECO:0000269\|PubMed:15629145, ECO:0000269\|PubMed:16384934, ECO:0000269\|PubMed:16597617, ECO:0000269\|PubMed:17311277, ECO:0000269\|PubMed:17623664, ECO:0000269\|PubMed:18374639, ECO:0000269\|PubMed:19103595, ECO:0000269\|PubMed:19387476, ECO:0000269\|PubMed:19410646, ECO:0000269\|PubMed:21596750, ECO:0000269\|PubMed:8663044}.	FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

154_247

765

820.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

256_358

765

820.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

25_125

765

820.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

154_247

765

786.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

256_358

765

786.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

25_125

765

786.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

154_247

650

705.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

256_358

650

705.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

25_125

650

705.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

154_247

678

708.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

256_358

678

708.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

25_125

678

708.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

154_247

767

822.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

256_358

767

822.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

25_125

767

822.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

481_770

767

822.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

154_247

679

681.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

256_358

679

681.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

25_125

679

681.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

154_247

768

770.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

256_358

768

770.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

25_125

768

770.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

481_770

768

770.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

154_247

651

706.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

256_358

651

706.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

25_125

651

706.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

154_247

655

710.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

256_358

655

710.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

25_125

655

710.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

154_247

768

823.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

256_358

768

823.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

25_125

768

823.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

481_770

768

823.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

487_495

765

820.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

565_567

765

820.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

487_495

765

786.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

565_567

765

786.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

487_495

650

705.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

565_567

650

705.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

487_495

678

708.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

565_567

678

708.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

487_495

767

822.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

565_567

767

822.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

487_495

679

681.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

565_567

679

681.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

487_495

768

770.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

565_567

768

770.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

487_495

651

706.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

565_567

651

706.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

487_495

655

710.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

565_567

655

710.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

487_495

768

823.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

565_567

768

823.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

161_178

765

820.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

161_178

765

786.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

161_178

650

705.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

161_178

678

708.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

161_178

767

822.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

161_178

679

681.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

161_178

768

770.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

161_178

651

706.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

161_178

655

710.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

161_178

768

823.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

22_377

765

820.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

22_377

765

786.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

22_377

650

705.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

22_377

678

708.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

22_377

767

822.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

22_377

679

681.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

22_377

768

770.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

22_377

651

706.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

22_377

655

710.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

22_377

768

823.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

378_398

765

820.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

378_398

765

786.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

378_398

650

705.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

378_398

678

708.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

378_398

767

822.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

378_398

679

681.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

378_398

768

770.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

378_398

651

706.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

378_398

655

710.0

Transmembrane

Helical

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

378_398

768

823.0

Transmembrane

Helical

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000359172

318_322

484.0

Nucleotide binding

NAD

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000359172

397_399

484.0

Nucleotide binding

NAD

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000369799

318_322

531.0

Nucleotide binding

NAD

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000369799

397_399

531.0

Nucleotide binding

NAD

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000393614

318_322

484.0

Nucleotide binding

NAD

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000393614

397_399

484.0

Nucleotide binding

NAD

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000359172

281_448

484.0

Region

NAD binding

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000359172

520_530

484.0

Region

PDZ-binding

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000359172

65_92

484.0

Region

PEST

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000369799

281_448

531.0

Region

NAD binding

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000369799

520_530

531.0

Region

PDZ-binding

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000369799

65_92

531.0

Region

PEST

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000393614

281_448

484.0

Region

NAD binding

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000393614

520_530

484.0

Region

PDZ-binding

Tgene

AHCYL1

chr10:123243212

chr1:110551654

ENST00000393614

65_92

484.0

Region

PEST

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

481_770

765

820.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

481_770

765

786.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

481_770

650

705.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

481_770

678

708.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

154_247

255.0

Domain

Note=Ig-like C2-type 2

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

256_358

255.0

Domain

Note=Ig-like C2-type 3

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

25_125

255.0

Domain

Note=Ig-like C2-type 1

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

481_770

255.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

481_770

679

681.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

481_770

651

706.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

481_770

655

710.0

Domain

Protein kinase

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

487_495

255.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

565_567

255.0

Nucleotide binding

ATP

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

161_178

255.0

Region

Note=Heparin-binding

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000346997

399_821

765

820.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000351936

399_821

765

786.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000356226

399_821

650

705.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000357555

399_821

678

708.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000358487

399_821

767

822.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

22_377

255.0

Topological domain

Extracellular

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

399_821

255.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000360144

399_821

679

681.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369056

399_821

768

770.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369060

399_821

651

706.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000369061

399_821

655

710.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000457416

399_821

768

823.0

Topological domain

Cytoplasmic

Hgene

FGFR2

chr10:123243212

chr1:110551654

ENST00000359354

378_398

255.0

Transmembrane

Helical

Top

Fusion Gene Sequence for FGFR2-AHCYL1

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>30273_30273_1_FGFR2-AHCYL1_FGFR2_chr10_123243212_ENST00000346997_AHCYL1_chr1_110551654_ENST00000369799_length(transcript)=5835nt_BP=2307nt
GGTACCGTAACCATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTGGCCCGGCCCTCCTTCAGT
TTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAG
TCGCTAGAGGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGGCCCAACAATAGGACAGTG
CTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAA
ACTTGGTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCGGAAGATTTTGTCAGTGAG
AACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAG
TTTCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAGGAGCATCGCATTGGAGGC
TACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGAA
TACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCCGGACTGCCGGCAAATGCC
TCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGAAAAG
AACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCGCCGGTGTTAACACCACGGACAAAGAGATTGAGGTT
CTCTATATTCGGAATGTAACTTTTGAGGACGCTGGGGAATATACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTCTGCATGG
TTGACAGTTCTGCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTC
TTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCAC
AAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACA
ACACGCCTCTCTTCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGA
GATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCC
AAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATG
AAGATGATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCT
AAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATG
ACCTTCAAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCA
GCCAGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAA
AAGACCACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCC
TTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAA
GGACACAGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGACCA
ACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGAGCAAATCCAGTTTGCTGATGACATGCAGGAGTTC
ACCAAATTCCCCACCAAAACTGGCCGAAGATCTTTGTCTCGCTCGATCTCACAGTCCTCCACTGACAGCTACAGTTCAGCTGCATCCTAC
ACAGATAGCTCTGATGATGAGGTTTCTCCCCGAGAGAAGCAGCAAACCAACTCCAAGGGCAGCAGCAATTTCTGTGTGAAGAACATCAAG
CAGGCAGAATTTGGACGCCGGGAGATTGAGATTGCAGAGCAAGACATGTCTGCTCTGATTTCACTCAGGAAACGTGCTCAGGGGGAGAAG
CCCTTGGCTGGTGCTAAAATAGTGGGCTGTACACACATCACAGCCCAGACAGCGGTGTTGATTGAGACACTCTGTGCCCTGGGGGCTCAG
TGCCGCTGGTCTGCTTGTAACATCTACTCAACTCAGAATGAAGTAGCTGCAGCACTGGCTGAGGCTGGAGTTGCAGTGTTCGCTTGGAAG
GGCGAGTCAGAAGATGACTTCTGGTGGTGTATTGACCGCTGTGTGAACATGGATGGGTGGCAGGCCAACATGATCCTGGATGATGGGGGA
GACTTAACCCACTGGGTTTATAAGAAGTATCCAAACGTGTTTAAGAAGATCCGAGGCATTGTGGAAGAGAGCGTGACTGGTGTTCACAGG
CTGTATCAGCTCTCCAAAGCTGGGAAGCTCTGTGTTCCGGCCATGAACGTCAATGATTCTGTTACCAAACAGAAGTTTGATAACTTGTAC
TGCTGCCGAGAATCCATTTTGGATGGCCTGAAGAGGACCACAGATGTGATGTTTGGTGGGAAACAAGTGGTGGTGTGTGGCTATGGTGAG
GTAGGCAAGGGCTGCTGTGCTGCTCTCAAAGCTCTTGGAGCAATTGTCTACATTACCGAAATCGACCCCATCTGTGCTCTGCAGGCCTGC
ATGGATGGGTTCAGGGTGGTAAAGCTAAATGAAGTCATCCGGCAAGTCGATGTCGTAATAACTTGCACAGGAAATAAGAATGTAGTGACA
CGGGAGCACTTGGATCGCATGAAAAACAGTTGTATCGTATGCAATATGGGCCACTCCAACACAGAAATCGATGTGACCAGCCTCCGCACT
CCGGAGCTGACGTGGGAGCGAGTACGTTCTCAGGTGGACCATGTCATCTGGCCAGATGGCAAACGAGTTGTCCTCCTGGCAGAGGGTCGT
CTACTCAATTTGAGCTGCTCCACAGTTCCCACCTTTGTTCTGTCCATCACAGCCACAACACAGGCTTTGGCACTGATAGAACTCTATAAT
GCACCCGAGGGGCGATACAAGCAGGATGTGTACTTGCTTCCTAAGAAAATGGATGAATACGTTGCCAGCTTGCATCTGCCATCATTTGAT
GCCCACCTTACAGAGCTGACAGATGACCAAGCAAAATATCTGGGACTCAACAAAAATGGGCCATTCAAACCTAATTATTACAGATACTAA
TGGACCATACTACCAAGGACCAGTCCACCTGAACCACACACTCTAAAGAAATATTTTTTAAGATAACTTTTATTTTCTTCTTACTCCTTT
CCTCTTGATTTTTTTCCTATAATTTCATTCTTGTTTTTTCATCTCATTATCCAAGTTCTGCAGACCACACAGGAACTTGCTTCATGGCTC
TTTAGATGAAATAGAAGTTCAGGGTTCCTCACTCTAGTCACTAAAGAAGGATTTTACTCTCCCAGCCCAGAAAGGTGATTCTTTCTTTAC
CATTTCTGGGGACTTTAGTCTTAATTAGGTACCTTATTAACAGGAAATGCTAAGGTACCTTCTCTGTGGAACAATCTGCAATGTCTAAAT
CGCCTTAAAAGAGCCCATTTCTTAGCTGCTGAAATCAGTGCTCTTTCACTTCTTCAGAGAAGCAGGGATGGTACCTACCCGGCAGGTAGG
TTAGATGTGGGTGGTGCATGTTAATTTCCCTTAGAAGTTCCAAGCCCTGTTTCCTGCGTAAAGGTGGTATGTCCAGTTCAGAGATGTGTA
TAATGAGCATGGCTTGTTAAGATCAGGAGGCCCACTTGGATTTATAGTATAGCCCTTCCTCCACTCCCACCAGACTTGCTCATTTTTCGA
GTTTTTAACTAGACTACACTCTATTGAGTTTAATTTTGTCCTCTAGGATTTATTTCTGTTGTCCAAAAAAAAAAAAAAAGAAAAGAAAAA
TTAAGGAGAATTTTTGGTGTTAATGCTGAGGAATTGCTTGAGTGGTTAGTTGTTACCAATTTCTCTTTTGAACCTTTGGAGCTAAGGATG
CTGAGTCTAGAGAAATGCTAGTCTCAAGCCCTGTTAAGTCCCTCTGTTTCTAGCCCGTAGTTCATAGCATCAGTGAACTGGAGCCACAAC
AGCAAATTCTATCAGCTGTGTACCATACAGCTTGTGCTGAAGGCGAATTTCTTGAGCCATTACTCAGTATAAAGCACTGAGTTCTATCTT
TAGGATTTATCTTTAAGAGCAAATTTCTGGTCAGCTGTGCTTCTGCAACCTAAAATATTTAAAGGGAGGTAGGTGTGGGCAGGAGGAGGA
ATGATAAATTGGGCCAGGGCAAGAAAAATCTAGCTTCATATAATTTGTCTGGGACTATACACCCTATATAATGTTAGTTTTACAGAAGTA
ATATGACTTTTGATTGCTACATACCACAAAGAGTTTATGAACTGAGATCATAAAGGGCAACTGATGTGTGAAGAAAGTAGTCAGTACATC
CTGGCTCATGCTCTGAAAGAATATCCAGAGAGGCTCTCTCAAAGATCAGGGAGATGTATTCCCATGCCATGCACCCTGCTTCCCAGCATT
TCTGCATGGTCAAGTGAGCTTTATGCTCATGAGCTTTAAGTATATAATTATCCAGGATTTTAAATCCTCAACTTGTTCTAGCTTGTGATC
CCTCAAAGTTGGGTCATACGTTAGTGCTAGATACTAGAAATTTTCACTTTTCCACTGATCAGAGAGACAGACATTAAAAACAAAAATAGA
AGAAAGGAAAGCTTTCACCCTGCAGCTTCTTAGCAGGGAACAATTGTCTTGCCAAAACTTTTTTCCCTTTTCTCTCCCATTTTCTTTTAC
CCAATCCCTTCTTACTCCTTGCCAGTGTGACCATGCTTTCTTCTCTGTAGATGTTAACAGTTAAGGCCTATTTTCCTCGGGCACTTAACC
AACCAATCAGAACACCACATCTGTTAGGGGAGGTAACCTGGCCAACAGTGTATCCATCACGTTAGCCCTGCTGGAGGGAAGGGACCCACA
TTCACCTGCCCTCTGACCTGCCCCTTGATCCCATATCTATTACCGTGTCCATAGGAATAATAGGTAAGGGCTCTGTCTCTGTCAAGCCAT
GTAACAAAGGACACTGTTAAAAAAAAAAAAAAGTCTGGCATCAGAGGGAGCATGTGGAGAGCAACTTGGGAAGAACAAGTTCATTTTGTA

>30273_30273_1_FGFR2-AHCYL1_FGFR2_chr10_123243212_ENST00000346997_AHCYL1_chr1_110551654_ENST00000369799_length(amino acids)=1255AA_BP=765
MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGE
YLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP
AGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVV
GGDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL
PAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTKRIPLRRQVSAESSSSMNSNTPLVRITTRLS
STADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIG
KHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLAARNV
LVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRM
DKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEQIQFADDMQEFTKFPTKTGRRSLSRSISQSSTDSYSSAASYTDSS
DDEVSPREKQQTNSKGSSNFCVKNIKQAEFGRREIEIAEQDMSALISLRKRAQGEKPLAGAKIVGCTHITAQTAVLIETLCALGAQCRWS
ACNIYSTQNEVAAALAEAGVAVFAWKGESEDDFWWCIDRCVNMDGWQANMILDDGGDLTHWVYKKYPNVFKKIRGIVEESVTGVHRLYQL
SKAGKLCVPAMNVNDSVTKQKFDNLYCCRESILDGLKRTTDVMFGGKQVVVCGYGEVGKGCCAALKALGAIVYITEIDPICALQACMDGF
RVVKLNEVIRQVDVVITCTGNKNVVTREHLDRMKNSCIVCNMGHSNTEIDVTSLRTPELTWERVRSQVDHVIWPDGKRVVLLAEGRLLNL

--------------------------------------------------------------
>30273_30273_2_FGFR2-AHCYL1_FGFR2_chr10_123243212_ENST00000369056_AHCYL1_chr1_110551654_ENST00000369799_length(transcript)=5856nt_BP=2328nt
GGACCGGGGATTGGTACCGTAACCATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTGGCCCGG
CCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCT
GCGCCAGGGGAGTCGCTAGAGGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGGCCCAAC
AATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACT
GTAGACAGTGAAACTTGGTACTTCATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCGGAAGAT
TTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAAAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCC
AACACTGTCAAGTTTCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAGGAGCAT
CGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTA
GTGGAGAATGAATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCCGGACTG
CCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAG
CACGTGGAAAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGCACTCGGGGATAAATAGTTCCAATGCA
GAAGTGCTGGCTCTGTTCAATGTGACCGAGGCGGATGCTGGGGAATATATATGTAAGGTCTCCAATTATATAGGGCAGGCCAACCAGTCT
GCCTGGCTCACTGTCCTGCCAAAACAGCAAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATTTAC
TGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGC
CAGCCGGCTGTGCACAAGCTGACCAAACGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCCAAC
ACCCCGCTGGTGAGGATAACAACACGCCTCTCTTCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGAC
CCAAAATGGGAGTTTCCAAGAGATAAGCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCAGTG
GGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCTG
GTGTCAGAGATGGAGATGATGAAGATGATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTCTAT
GTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACATTAAC
CGTGTTCCTGAGGAGCAGATGACCTTCAAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAA
TGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAGAGATATC
AACAATATAGACTATTACAAAAAGACCACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACT
CATCAGAGTGATGTCTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCCCGTGGAGGAA
CTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCAT
GCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGAGCAAATCCAGTTT
GCTGATGACATGCAGGAGTTCACCAAATTCCCCACCAAAACTGGCCGAAGATCTTTGTCTCGCTCGATCTCACAGTCCTCCACTGACAGC
TACAGTTCAGCTGCATCCTACACAGATAGCTCTGATGATGAGGTTTCTCCCCGAGAGAAGCAGCAAACCAACTCCAAGGGCAGCAGCAAT
TTCTGTGTGAAGAACATCAAGCAGGCAGAATTTGGACGCCGGGAGATTGAGATTGCAGAGCAAGACATGTCTGCTCTGATTTCACTCAGG
AAACGTGCTCAGGGGGAGAAGCCCTTGGCTGGTGCTAAAATAGTGGGCTGTACACACATCACAGCCCAGACAGCGGTGTTGATTGAGACA
CTCTGTGCCCTGGGGGCTCAGTGCCGCTGGTCTGCTTGTAACATCTACTCAACTCAGAATGAAGTAGCTGCAGCACTGGCTGAGGCTGGA
GTTGCAGTGTTCGCTTGGAAGGGCGAGTCAGAAGATGACTTCTGGTGGTGTATTGACCGCTGTGTGAACATGGATGGGTGGCAGGCCAAC
ATGATCCTGGATGATGGGGGAGACTTAACCCACTGGGTTTATAAGAAGTATCCAAACGTGTTTAAGAAGATCCGAGGCATTGTGGAAGAG
AGCGTGACTGGTGTTCACAGGCTGTATCAGCTCTCCAAAGCTGGGAAGCTCTGTGTTCCGGCCATGAACGTCAATGATTCTGTTACCAAA
CAGAAGTTTGATAACTTGTACTGCTGCCGAGAATCCATTTTGGATGGCCTGAAGAGGACCACAGATGTGATGTTTGGTGGGAAACAAGTG
GTGGTGTGTGGCTATGGTGAGGTAGGCAAGGGCTGCTGTGCTGCTCTCAAAGCTCTTGGAGCAATTGTCTACATTACCGAAATCGACCCC
ATCTGTGCTCTGCAGGCCTGCATGGATGGGTTCAGGGTGGTAAAGCTAAATGAAGTCATCCGGCAAGTCGATGTCGTAATAACTTGCACA
GGAAATAAGAATGTAGTGACACGGGAGCACTTGGATCGCATGAAAAACAGTTGTATCGTATGCAATATGGGCCACTCCAACACAGAAATC
GATGTGACCAGCCTCCGCACTCCGGAGCTGACGTGGGAGCGAGTACGTTCTCAGGTGGACCATGTCATCTGGCCAGATGGCAAACGAGTT
GTCCTCCTGGCAGAGGGTCGTCTACTCAATTTGAGCTGCTCCACAGTTCCCACCTTTGTTCTGTCCATCACAGCCACAACACAGGCTTTG
GCACTGATAGAACTCTATAATGCACCCGAGGGGCGATACAAGCAGGATGTGTACTTGCTTCCTAAGAAAATGGATGAATACGTTGCCAGC
TTGCATCTGCCATCATTTGATGCCCACCTTACAGAGCTGACAGATGACCAAGCAAAATATCTGGGACTCAACAAAAATGGGCCATTCAAA
CCTAATTATTACAGATACTAATGGACCATACTACCAAGGACCAGTCCACCTGAACCACACACTCTAAAGAAATATTTTTTAAGATAACTT
TTATTTTCTTCTTACTCCTTTCCTCTTGATTTTTTTCCTATAATTTCATTCTTGTTTTTTCATCTCATTATCCAAGTTCTGCAGACCACA
CAGGAACTTGCTTCATGGCTCTTTAGATGAAATAGAAGTTCAGGGTTCCTCACTCTAGTCACTAAAGAAGGATTTTACTCTCCCAGCCCA
GAAAGGTGATTCTTTCTTTACCATTTCTGGGGACTTTAGTCTTAATTAGGTACCTTATTAACAGGAAATGCTAAGGTACCTTCTCTGTGG
AACAATCTGCAATGTCTAAATCGCCTTAAAAGAGCCCATTTCTTAGCTGCTGAAATCAGTGCTCTTTCACTTCTTCAGAGAAGCAGGGAT
GGTACCTACCCGGCAGGTAGGTTAGATGTGGGTGGTGCATGTTAATTTCCCTTAGAAGTTCCAAGCCCTGTTTCCTGCGTAAAGGTGGTA
TGTCCAGTTCAGAGATGTGTATAATGAGCATGGCTTGTTAAGATCAGGAGGCCCACTTGGATTTATAGTATAGCCCTTCCTCCACTCCCA
CCAGACTTGCTCATTTTTCGAGTTTTTAACTAGACTACACTCTATTGAGTTTAATTTTGTCCTCTAGGATTTATTTCTGTTGTCCAAAAA
AAAAAAAAAAGAAAAGAAAAATTAAGGAGAATTTTTGGTGTTAATGCTGAGGAATTGCTTGAGTGGTTAGTTGTTACCAATTTCTCTTTT
GAACCTTTGGAGCTAAGGATGCTGAGTCTAGAGAAATGCTAGTCTCAAGCCCTGTTAAGTCCCTCTGTTTCTAGCCCGTAGTTCATAGCA
TCAGTGAACTGGAGCCACAACAGCAAATTCTATCAGCTGTGTACCATACAGCTTGTGCTGAAGGCGAATTTCTTGAGCCATTACTCAGTA
TAAAGCACTGAGTTCTATCTTTAGGATTTATCTTTAAGAGCAAATTTCTGGTCAGCTGTGCTTCTGCAACCTAAAATATTTAAAGGGAGG
TAGGTGTGGGCAGGAGGAGGAATGATAAATTGGGCCAGGGCAAGAAAAATCTAGCTTCATATAATTTGTCTGGGACTATACACCCTATAT
AATGTTAGTTTTACAGAAGTAATATGACTTTTGATTGCTACATACCACAAAGAGTTTATGAACTGAGATCATAAAGGGCAACTGATGTGT
GAAGAAAGTAGTCAGTACATCCTGGCTCATGCTCTGAAAGAATATCCAGAGAGGCTCTCTCAAAGATCAGGGAGATGTATTCCCATGCCA
TGCACCCTGCTTCCCAGCATTTCTGCATGGTCAAGTGAGCTTTATGCTCATGAGCTTTAAGTATATAATTATCCAGGATTTTAAATCCTC
AACTTGTTCTAGCTTGTGATCCCTCAAAGTTGGGTCATACGTTAGTGCTAGATACTAGAAATTTTCACTTTTCCACTGATCAGAGAGACA
GACATTAAAAACAAAAATAGAAGAAAGGAAAGCTTTCACCCTGCAGCTTCTTAGCAGGGAACAATTGTCTTGCCAAAACTTTTTTCCCTT
TTCTCTCCCATTTTCTTTTACCCAATCCCTTCTTACTCCTTGCCAGTGTGACCATGCTTTCTTCTCTGTAGATGTTAACAGTTAAGGCCT
ATTTTCCTCGGGCACTTAACCAACCAATCAGAACACCACATCTGTTAGGGGAGGTAACCTGGCCAACAGTGTATCCATCACGTTAGCCCT
GCTGGAGGGAAGGGACCCACATTCACCTGCCCTCTGACCTGCCCCTTGATCCCATATCTATTACCGTGTCCATAGGAATAATAGGTAAGG
GCTCTGTCTCTGTCAAGCCATGTAACAAAGGACACTGTTAAAAAAAAAAAAAAGTCTGGCATCAGAGGGAGCATGTGGAGAGCAACTTGG
GAAGAACAAGTTCATTTTGTATTGAATGATTTTTAATGAATGCAATATTAATCCTTGCAGATGAGCAATAATCATTAAAATCGATTAAAA

>30273_30273_2_FGFR2-AHCYL1_FGFR2_chr10_123243212_ENST00000369056_AHCYL1_chr1_110551654_ENST00000369799_length(amino acids)=1258AA_BP=768
MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGE
YLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP
AGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVV
GGDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKHSGINSSNAEVLALFNVTEADAGEYICKVSNYIGQANQSAWLTVLPK
QQAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTKRIPLRRQVTVSAESSSSMNSNTPLVRITT
RLSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMK
MIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLAA
RNVLVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEG
HRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEQIQFADDMQEFTKFPTKTGRRSLSRSISQSSTDSYSSAASYT
DSSDDEVSPREKQQTNSKGSSNFCVKNIKQAEFGRREIEIAEQDMSALISLRKRAQGEKPLAGAKIVGCTHITAQTAVLIETLCALGAQC
RWSACNIYSTQNEVAAALAEAGVAVFAWKGESEDDFWWCIDRCVNMDGWQANMILDDGGDLTHWVYKKYPNVFKKIRGIVEESVTGVHRL
YQLSKAGKLCVPAMNVNDSVTKQKFDNLYCCRESILDGLKRTTDVMFGGKQVVVCGYGEVGKGCCAALKALGAIVYITEIDPICALQACM
DGFRVVKLNEVIRQVDVVITCTGNKNVVTREHLDRMKNSCIVCNMGHSNTEIDVTSLRTPELTWERVRSQVDHVIWPDGKRVVLLAEGRL

--------------------------------------------------------------
>30273_30273_3_FGFR2-AHCYL1_FGFR2_chr10_123243212_ENST00000369061_AHCYL1_chr1_110551654_ENST00000369799_length(transcript)=5643nt_BP=2115nt
TGACTGCAGCAGCAGCGGCAGCGCCTCGGTTCCTGAGCCCACCGCAGGCTGAAGGCATTGCGCGTAGTCCATGCCCGTAGAGGAAGTGTG
CAGATGGGATTAACGTCCACATGGAGATATGGAAGAGGACCGGGGATTGGTACCGTAACCATGGTCAGCTGGGGTCGTTTCATCTGCCTG
GTCGTGGTCACCATGGCAACCTTGTCCCTGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACC
AAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGAGGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATC
AGTTGGACTAAGGATGGGGTGCACTTGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGA
GACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTGGTACTTCATGGTGAATGTCACAGATGCCATCTCATCC
GGAGATGATGAGGATGACACCGATGGTGCGGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAA
AAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTTTCGCTGCCCAGCCGGGGGGAACCCAATGCCAACCATGCGG
TGGCTGAAAAACGGGAAGGAGTTTAAGCAGGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGT
GTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGAATACGGGTCCATCAATCACACGTACCACCTGGATGTTGTGGCG
CCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATTTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTG
GTAACAGTCATCCTGTGCCGAATGAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCACAAGCTGACCAAACGTATC
CCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACACGCCTCTCT
TCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGAGATAAGCTGACA
CTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCAGTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTC
ACCGTGGCCGTGAAGATGTTGAAAGATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATGATTGGG
AAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTC
CGAGAATACCTCCGAGCCCGGAGGCCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATGACCTTCAAGGAC
TTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAAAAATGTATTCATCGAGATTTAGCAGCCAGAAATGTT
TTGGTAACAGAAAACAATGTGATGAAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACCACCAAT
GGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCATCAGAGTGATGTCTGGTCCTTCGGGGTGTTA
ATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATG
GATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAG
TTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGAGCAAATCCAGTTTGCTGATGACATGCAGGAGTTCACCAAATTCCCC
ACCAAAACTGGCCGAAGATCTTTGTCTCGCTCGATCTCACAGTCCTCCACTGACAGCTACAGTTCAGCTGCATCCTACACAGATAGCTCT
GATGATGAGGTTTCTCCCCGAGAGAAGCAGCAAACCAACTCCAAGGGCAGCAGCAATTTCTGTGTGAAGAACATCAAGCAGGCAGAATTT
GGACGCCGGGAGATTGAGATTGCAGAGCAAGACATGTCTGCTCTGATTTCACTCAGGAAACGTGCTCAGGGGGAGAAGCCCTTGGCTGGT
GCTAAAATAGTGGGCTGTACACACATCACAGCCCAGACAGCGGTGTTGATTGAGACACTCTGTGCCCTGGGGGCTCAGTGCCGCTGGTCT
GCTTGTAACATCTACTCAACTCAGAATGAAGTAGCTGCAGCACTGGCTGAGGCTGGAGTTGCAGTGTTCGCTTGGAAGGGCGAGTCAGAA
GATGACTTCTGGTGGTGTATTGACCGCTGTGTGAACATGGATGGGTGGCAGGCCAACATGATCCTGGATGATGGGGGAGACTTAACCCAC
TGGGTTTATAAGAAGTATCCAAACGTGTTTAAGAAGATCCGAGGCATTGTGGAAGAGAGCGTGACTGGTGTTCACAGGCTGTATCAGCTC
TCCAAAGCTGGGAAGCTCTGTGTTCCGGCCATGAACGTCAATGATTCTGTTACCAAACAGAAGTTTGATAACTTGTACTGCTGCCGAGAA
TCCATTTTGGATGGCCTGAAGAGGACCACAGATGTGATGTTTGGTGGGAAACAAGTGGTGGTGTGTGGCTATGGTGAGGTAGGCAAGGGC
TGCTGTGCTGCTCTCAAAGCTCTTGGAGCAATTGTCTACATTACCGAAATCGACCCCATCTGTGCTCTGCAGGCCTGCATGGATGGGTTC
AGGGTGGTAAAGCTAAATGAAGTCATCCGGCAAGTCGATGTCGTAATAACTTGCACAGGAAATAAGAATGTAGTGACACGGGAGCACTTG
GATCGCATGAAAAACAGTTGTATCGTATGCAATATGGGCCACTCCAACACAGAAATCGATGTGACCAGCCTCCGCACTCCGGAGCTGACG
TGGGAGCGAGTACGTTCTCAGGTGGACCATGTCATCTGGCCAGATGGCAAACGAGTTGTCCTCCTGGCAGAGGGTCGTCTACTCAATTTG
AGCTGCTCCACAGTTCCCACCTTTGTTCTGTCCATCACAGCCACAACACAGGCTTTGGCACTGATAGAACTCTATAATGCACCCGAGGGG
CGATACAAGCAGGATGTGTACTTGCTTCCTAAGAAAATGGATGAATACGTTGCCAGCTTGCATCTGCCATCATTTGATGCCCACCTTACA
GAGCTGACAGATGACCAAGCAAAATATCTGGGACTCAACAAAAATGGGCCATTCAAACCTAATTATTACAGATACTAATGGACCATACTA
CCAAGGACCAGTCCACCTGAACCACACACTCTAAAGAAATATTTTTTAAGATAACTTTTATTTTCTTCTTACTCCTTTCCTCTTGATTTT
TTTCCTATAATTTCATTCTTGTTTTTTCATCTCATTATCCAAGTTCTGCAGACCACACAGGAACTTGCTTCATGGCTCTTTAGATGAAAT
AGAAGTTCAGGGTTCCTCACTCTAGTCACTAAAGAAGGATTTTACTCTCCCAGCCCAGAAAGGTGATTCTTTCTTTACCATTTCTGGGGA
CTTTAGTCTTAATTAGGTACCTTATTAACAGGAAATGCTAAGGTACCTTCTCTGTGGAACAATCTGCAATGTCTAAATCGCCTTAAAAGA
GCCCATTTCTTAGCTGCTGAAATCAGTGCTCTTTCACTTCTTCAGAGAAGCAGGGATGGTACCTACCCGGCAGGTAGGTTAGATGTGGGT
GGTGCATGTTAATTTCCCTTAGAAGTTCCAAGCCCTGTTTCCTGCGTAAAGGTGGTATGTCCAGTTCAGAGATGTGTATAATGAGCATGG
CTTGTTAAGATCAGGAGGCCCACTTGGATTTATAGTATAGCCCTTCCTCCACTCCCACCAGACTTGCTCATTTTTCGAGTTTTTAACTAG
ACTACACTCTATTGAGTTTAATTTTGTCCTCTAGGATTTATTTCTGTTGTCCAAAAAAAAAAAAAAAGAAAAGAAAAATTAAGGAGAATT
TTTGGTGTTAATGCTGAGGAATTGCTTGAGTGGTTAGTTGTTACCAATTTCTCTTTTGAACCTTTGGAGCTAAGGATGCTGAGTCTAGAG
AAATGCTAGTCTCAAGCCCTGTTAAGTCCCTCTGTTTCTAGCCCGTAGTTCATAGCATCAGTGAACTGGAGCCACAACAGCAAATTCTAT
CAGCTGTGTACCATACAGCTTGTGCTGAAGGCGAATTTCTTGAGCCATTACTCAGTATAAAGCACTGAGTTCTATCTTTAGGATTTATCT
TTAAGAGCAAATTTCTGGTCAGCTGTGCTTCTGCAACCTAAAATATTTAAAGGGAGGTAGGTGTGGGCAGGAGGAGGAATGATAAATTGG
GCCAGGGCAAGAAAAATCTAGCTTCATATAATTTGTCTGGGACTATACACCCTATATAATGTTAGTTTTACAGAAGTAATATGACTTTTG
ATTGCTACATACCACAAAGAGTTTATGAACTGAGATCATAAAGGGCAACTGATGTGTGAAGAAAGTAGTCAGTACATCCTGGCTCATGCT
CTGAAAGAATATCCAGAGAGGCTCTCTCAAAGATCAGGGAGATGTATTCCCATGCCATGCACCCTGCTTCCCAGCATTTCTGCATGGTCA
AGTGAGCTTTATGCTCATGAGCTTTAAGTATATAATTATCCAGGATTTTAAATCCTCAACTTGTTCTAGCTTGTGATCCCTCAAAGTTGG
GTCATACGTTAGTGCTAGATACTAGAAATTTTCACTTTTCCACTGATCAGAGAGACAGACATTAAAAACAAAAATAGAAGAAAGGAAAGC
TTTCACCCTGCAGCTTCTTAGCAGGGAACAATTGTCTTGCCAAAACTTTTTTCCCTTTTCTCTCCCATTTTCTTTTACCCAATCCCTTCT
TACTCCTTGCCAGTGTGACCATGCTTTCTTCTCTGTAGATGTTAACAGTTAAGGCCTATTTTCCTCGGGCACTTAACCAACCAATCAGAA
CACCACATCTGTTAGGGGAGGTAACCTGGCCAACAGTGTATCCATCACGTTAGCCCTGCTGGAGGGAAGGGACCCACATTCACCTGCCCT
CTGACCTGCCCCTTGATCCCATATCTATTACCGTGTCCATAGGAATAATAGGTAAGGGCTCTGTCTCTGTCAAGCCATGTAACAAAGGAC
ACTGTTAAAAAAAAAAAAAAGTCTGGCATCAGAGGGAGCATGTGGAGAGCAACTTGGGAAGAACAAGTTCATTTTGTATTGAATGATTTT

>30273_30273_3_FGFR2-AHCYL1_FGFR2_chr10_123243212_ENST00000369061_AHCYL1_chr1_110551654_ENST00000369799_length(amino acids)=1179AA_BP=689
MKALRVVHARRGSVQMGLTSTWRYGRGPGIGTVTMVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGE
SLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSE
NSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENE
YGSINHTYHLDVVAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTKRIPLRRQVTVSAESSSSM
NSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDL
SDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLA
SQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIP
VEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEQIQFADDMQEFTKFPTKTGRRSLSRSISQSS
TDSYSSAASYTDSSDDEVSPREKQQTNSKGSSNFCVKNIKQAEFGRREIEIAEQDMSALISLRKRAQGEKPLAGAKIVGCTHITAQTAVL
IETLCALGAQCRWSACNIYSTQNEVAAALAEAGVAVFAWKGESEDDFWWCIDRCVNMDGWQANMILDDGGDLTHWVYKKYPNVFKKIRGI
VEESVTGVHRLYQLSKAGKLCVPAMNVNDSVTKQKFDNLYCCRESILDGLKRTTDVMFGGKQVVVCGYGEVGKGCCAALKALGAIVYITE
IDPICALQACMDGFRVVKLNEVIRQVDVVITCTGNKNVVTREHLDRMKNSCIVCNMGHSNTEIDVTSLRTPELTWERVRSQVDHVIWPDG
KRVVLLAEGRLLNLSCSTVPTFVLSITATTQALALIELYNAPEGRYKQDVYLLPKKMDEYVASLHLPSFDAHLTELTDDQAKYLGLNKNG

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for FGFR2-AHCYL1

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner	Gene	Hbp	Tbp	ENST	Strand	BPexon	TotalExon	Protein feature loci	*BPloci	TotalLen	Still interaction with
Tgene	AHCYL1	chr10:123243212	chr1:110551654	ENST00000359172		0	17	138_201	0	484.0	BCL2L10
Tgene	AHCYL1	chr10:123243212	chr1:110551654	ENST00000369799		0	17	138_201	40.0	531.0	BCL2L10
Tgene	AHCYL1	chr10:123243212	chr1:110551654	ENST00000393614		0	17	138_201	0	484.0	BCL2L10

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for FGFR2-AHCYL1

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner	Gene	UniProtAcc	DrugBank ID	Drug name	Drug activity	Drug type	Drug status
Hgene	FGFR2	P21802	DB00039	Palifermin	Agonist\|Binder	Biotech	Approved
Hgene	FGFR2	P21802	DB00039	Palifermin	Agonist\|Binder	Biotech	Approved
Hgene	FGFR2	P21802	DB00039	Palifermin	Agonist\|Binder	Biotech	Approved
Hgene	FGFR2	P21802	DB00039	Palifermin	Agonist\|Binder	Biotech	Approved
Hgene	FGFR2	P21802	DB08896	Regorafenib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB08896	Regorafenib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB08896	Regorafenib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB08896	Regorafenib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB09079	Nintedanib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB09079	Nintedanib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB09079	Nintedanib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB09079	Nintedanib	Inhibitor	Small molecule	Approved
Hgene	FGFR2	P21802	DB10770	Foreskin fibroblast (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB10770	Foreskin fibroblast (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB10770	Foreskin fibroblast (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB10770	Foreskin fibroblast (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	FGFR2	P21802	DB01109	Heparin		Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB01109	Heparin		Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB01109	Heparin		Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB01109	Heparin		Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB08901	Ponatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB08901	Ponatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB08901	Ponatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB08901	Ponatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB09078	Lenvatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB09078	Lenvatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB09078	Lenvatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB09078	Lenvatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12147	Erdafitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12147	Erdafitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12147	Erdafitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB12147	Erdafitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15102	Pemigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15102	Pemigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15102	Pemigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15102	Pemigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15685	Selpercatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15685	Selpercatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15685	Selpercatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15685	Selpercatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15822	Pralsetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15822	Pralsetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15822	Pralsetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB15822	Pralsetinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	FGFR2	P21802	DB01041	Thalidomide	Antagonist	Small molecule	Approved\|Investigational\|Withdrawn
Hgene	FGFR2	P21802	DB01041	Thalidomide	Antagonist	Small molecule	Approved\|Investigational\|Withdrawn
Hgene	FGFR2	P21802	DB01041	Thalidomide	Antagonist	Small molecule	Approved\|Investigational\|Withdrawn
Hgene	FGFR2	P21802	DB01041	Thalidomide	Antagonist	Small molecule	Approved\|Investigational\|Withdrawn

Top

Related Diseases for FGFR2-AHCYL1

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	FGFR2	C2931196	Craniofacial dysostosis type 1	23	CTD_human;GENOMICS_ENGLAND;UNIPROT
Hgene	FGFR2	C0220658	Pfeiffer Syndrome	21	CTD_human;GENOMICS_ENGLAND;UNIPROT
Hgene	FGFR2	C0001193	Apert syndrome	19	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Hgene	FGFR2	C0795998	JACKSON-WEISS SYNDROME	10	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Hgene	FGFR2	C0175699	Saethre-Chotzen Syndrome	8	CTD_human;GENOMICS_ENGLAND;ORPHANET
Hgene	FGFR2	C1852406	Cutis Gyrata Syndrome of Beare And Stevenson	8	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Hgene	FGFR2	C2936791	Antley-Bixler Syndrome, Autosomal Dominant	7	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Hgene	FGFR2	C1510455	Acrocephalosyndactylia	6	CTD_human;ORPHANET
Hgene	FGFR2	C0265269	Lacrimoauriculodentodigital syndrome	5	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Hgene	FGFR2	C0010278	Craniosynostosis	4	CTD_human;GENOMICS_ENGLAND
Hgene	FGFR2	C1863389	Apert-Crouzon Disease	4	CTD_human
Hgene	FGFR2	C1865070	SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION	4	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Hgene	FGFR2	C0006142	Malignant neoplasm of breast	3	CTD_human;UNIPROT
Hgene	FGFR2	C0030044	Acrocephaly	3	CTD_human
Hgene	FGFR2	C0036341	Schizophrenia	3	PSYGENET
Hgene	FGFR2	C0221356	Brachycephaly	3	CTD_human
Hgene	FGFR2	C0265534	Scaphycephaly	3	CTD_human
Hgene	FGFR2	C0265535	Trigonocephaly	3	CTD_human
Hgene	FGFR2	C0376634	Craniofacial Abnormalities	3	CTD_human
Hgene	FGFR2	C0678222	Breast Carcinoma	3	CTD_human
Hgene	FGFR2	C1257931	Mammary Neoplasms, Human	3	CTD_human
Hgene	FGFR2	C1458155	Mammary Neoplasms	3	CTD_human
Hgene	FGFR2	C1833340	Synostotic Posterior Plagiocephaly	3	CTD_human
Hgene	FGFR2	C1860819	Metopic synostosis	3	CTD_human
Hgene	FGFR2	C2931150	Synostotic Anterior Plagiocephaly	3	CTD_human
Hgene	FGFR2	C3281247	BENT BONE DYSPLASIA SYNDROME	3	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Hgene	FGFR2	C4551902	Craniosynostosis, Type 1	3	CTD_human
Hgene	FGFR2	C4704874	Mammary Carcinoma, Human	3	CTD_human
Hgene	FGFR2	C0008925	Cleft Palate	2	CTD_human
Hgene	FGFR2	C0011570	Mental Depression	2	PSYGENET
Hgene	FGFR2	C0011581	Depressive disorder	2	PSYGENET
Hgene	FGFR2	C0024623	Malignant neoplasm of stomach	2	CGI;CTD_human
Hgene	FGFR2	C0038356	Stomach Neoplasms	2	CGI;CTD_human
Hgene	FGFR2	C1708349	Hereditary Diffuse Gastric Cancer	2	CTD_human
Hgene	FGFR2	C1837218	Cleft palate, isolated	2	CTD_human
Hgene	FGFR2	C0000772	Multiple congenital anomalies	1	CTD_human
Hgene	FGFR2	C0003090	Ankylosis	1	CTD_human
Hgene	FGFR2	C0005586	Bipolar Disorder	1	PSYGENET
Hgene	FGFR2	C0008924	Cleft upper lip	1	CTD_human
Hgene	FGFR2	C0010273	Craniofacial Dysostosis	1	CTD_human
Hgene	FGFR2	C0011757	Developmental Coordination Disorder	1	CTD_human
Hgene	FGFR2	C0014170	Endometrial Neoplasms	1	CTD_human
Hgene	FGFR2	C0018553	Hamartoma Syndrome, Multiple	1	CTD_human
Hgene	FGFR2	C0020796	Profound Mental Retardation	1	CTD_human
Hgene	FGFR2	C0023890	Liver Cirrhosis	1	CTD_human
Hgene	FGFR2	C0024121	Lung Neoplasms	1	CTD_human
Hgene	FGFR2	C0025363	Mental Retardation, Psychosocial	1	CTD_human
Hgene	FGFR2	C0026613	Motor Skills Disorders	1	CTD_human
Hgene	FGFR2	C0033975	Psychotic Disorders	1	PSYGENET
Hgene	FGFR2	C0037268	Skin Abnormalities	1	CTD_human
Hgene	FGFR2	C0037274	Dermatologic disorders	1	CTD_human
Hgene	FGFR2	C0038219	Status Dysraphicus	1	CTD_human
Hgene	FGFR2	C0040427	Tooth Abnormalities	1	CTD_human
Hgene	FGFR2	C0080178	Spina Bifida	1	CTD_human
Hgene	FGFR2	C0152423	Congenital small ears	1	GENOMICS_ENGLAND
Hgene	FGFR2	C0206698	Cholangiocarcinoma	1	CTD_human
Hgene	FGFR2	C0206762	Limb Deformities, Congenital	1	CTD_human
Hgene	FGFR2	C0239946	Fibrosis, Liver	1	CTD_human
Hgene	FGFR2	C0242379	Malignant neoplasm of lung	1	CTD_human
Hgene	FGFR2	C0265326	Bannayan-Riley-Ruvalcaba Syndrome	1	CTD_human
Hgene	FGFR2	C0266508	Rachischisis	1	CTD_human
Hgene	FGFR2	C0345905	Intrahepatic Cholangiocarcinoma	1	CTD_human
Hgene	FGFR2	C0349204	Nonorganic psychosis	1	PSYGENET
Hgene	FGFR2	C0391826	Lhermitte-Duclos disease	1	CTD_human
Hgene	FGFR2	C0476089	Endometrial Carcinoma	1	CGI;CTD_human
Hgene	FGFR2	C0524730	Odontome	1	CTD_human
Hgene	FGFR2	C0699791	Stomach Carcinoma	1	CGI;GENOMICS_ENGLAND
Hgene	FGFR2	C0917816	Mental deficiency	1	CTD_human
Hgene	FGFR2	C1450010	Plagiocephaly, Nonsynostotic	1	CTD_human
Hgene	FGFR2	C1860042	Antley-Bixler Syndrome with Disordered Steroidogenesis	1	CTD_human
Hgene	FGFR2	C1867564	SCAPHOCEPHALY AND AXENFELD-RIEGER ANOMALY	1	GENOMICS_ENGLAND
Hgene	FGFR2	C1959582	PTEN Hamartoma Tumor Syndrome	1	CTD_human
Hgene	FGFR2	C2350233	Antley-Bixler Syndrome Phenotype	1	CTD_human
Hgene	FGFR2	C3267076	Familial scaphocephaly syndrome	1	GENOMICS_ENGLAND
Hgene	FGFR2	C3714756	Intellectual Disability	1	CTD_human
Hgene	FGFR2	C3805278	Extrahepatic Cholangiocarcinoma	1	CTD_human

Fusion Gene Studies in Kim Lab

Fusion gene:FGFR2-AHCYL1 (FusionGDB2 ID:HG2263TG10768)

Fusion Gene Summary for FGFR2-AHCYL1

Fusion Gene ORF analysis for FGFR2-AHCYL1

Fusion Genomic Features for FGFR2-AHCYL1

Fusion Protein Features for FGFR2-AHCYL1

Fusion Gene Sequence for FGFR2-AHCYL1

Fusion Gene PPI Analysis for FGFR2-AHCYL1

Related Drugs for FGFR2-AHCYL1

Related Diseases for FGFR2-AHCYL1

Fusion Gene Studies
in Kim Lab